| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $31,425 | 1 | 33 |
Sells | $59,360 | 2 | 67 |
| Pfeifer Andrea | Chief Executive Officer | 1 | $31,425 | 2 | $59,360 | $-27,935 |
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. …
Over the last 12 months, insiders at AC Immune S.A. have bought $31,425 and sold $59,360 worth of AC Immune S.A. stock.
On average, over the past 5 years, insiders at AC Immune S.A. have bought $31,425 and sold $59,360 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Pfeifer Andrea (Chief Executive Officer) — $31,425.
The last purchase of 10,000 shares for transaction amount of $31,425 was made by Pfeifer Andrea (Chief Executive Officer) on 2026‑04‑15.
| 2026-05-15 | Sale | Pfeifer Andrea | Chief Executive Officer | 10,000 0.0098% | $2.79 | $27,935 | -10.39% | |
| 2026-04-15 | Sale | Pfeifer Andrea | Chief Executive Officer | 10,000 0.0098% | $3.14 | $31,425 | -18.63% | |
| 2026-04-15 | Pfeifer Andrea | Chief Executive Officer | 10,000 0.0098% | $3.14 | $31,425 | -18.63% |
| Increased Positions | 22 | +53.66% | 2M | +7.16% |
| Decreased Positions | 16 | -39.02% | 610,840 | -2.48% |
| New Positions | 7 | New | 1M | New |
| Sold Out Positions | 6 | Sold Out | 489,189 | Sold Out |
| Total Postitions | 47 | +14.63% | 26M | +4.68% |